Oncol Res Treat. 2018;41(5):316-326. doi: 10.1159/000486681. Epub 2018 Mar 23.
Long-acting granulocyte colony-stimulating factor (G-CSF) preparations are increasingly used in the management of chemotherapy-associated neutropenia. Due to the fact that they only need to be administered once following chemotherapy, they are more convenient for patients and easier to use in the clinical routine for physicians than short-term G-CSF preparations. Although the efficacy of these growth factors is generally accepted, there remains some concern regarding their safety. In this article we address safety concerns for long-acting growth factors by providing basic information and available data around important clinical issues that may be helpful for the decision to use or not to use these factors in individual clinical situations. After a critical review of the literature, regarding theoretical considerations based on the physiology of hematopoiesis, data from clinical studies show that long-acting G-CSF preparations can be applied safely in approved indications and are broadly beneficial for patients at risk undergoing chemotherapy.
长效粒细胞集落刺激因子（G-CSF）制剂在化疗相关性中性粒细胞减少症的治疗中越来越多地被应用。由于它们仅需在化疗后使用一次，因此与短期 G-CSF 制剂相比，对患者更加方便，也更便于医生在临床常规中使用。尽管这些生长因子的疗效已被广泛认可，但它们的安全性仍存在一些问题。在本文中，我们通过提供有关重要临床问题的基本知识和可用数据，解决长效生长因子的安全性问题，这些问题可能有助于在个体化临床情况下决定使用或不使用这些因子。在对基于造血生理学的理论考虑进行批判性回顾后，来自临床研究的数据表明，长效 G-CSF 制剂可在批准的适应证中安全应用，并且广泛有益于接受化疗的高危患者。
